Phillip Md Et Al Frost Buys 78,000 Shares of Opko Health Inc. (OPK) Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 78,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was purchased at an average cost of $4.22 per share, for a total transaction of $329,160.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $12,950,973.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, February 5th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.14 per share, for a total transaction of $207,000.00.
  • On Friday, February 2nd, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.30 per share, for a total transaction of $236,500.00.
  • On Wednesday, January 31st, Phillip Md Et Al Frost bought 65,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.47 per share, for a total transaction of $290,550.00.
  • On Friday, January 26th, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.90 per share, for a total transaction of $269,500.00.
  • On Wednesday, January 24th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.89 per share, for a total transaction of $489,000.00.
  • On Monday, January 22nd, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.40 per share, for a total transaction of $440,000.00.

Shares of Opko Health Inc. (OPK) opened at $4.15 on Thursday. The firm has a market capitalization of $2,427.82, a PE ratio of -18.82 and a beta of 1.42. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66. Opko Health Inc. has a 12-month low of $4.01 and a 12-month high of $8.92.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The company had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. Opko Health’s revenue for the quarter was down 11.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.03) earnings per share. equities analysts anticipate that Opko Health Inc. will post -0.27 earnings per share for the current fiscal year.

OPK has been the topic of several research reports. Cantor Fitzgerald set a $20.00 target price on Opko Health and gave the company a “buy” rating in a research report on Wednesday, October 25th. Zacks Investment Research raised Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Finally, BidaskClub downgraded Opko Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $13.34.

Institutional investors and hedge funds have recently made changes to their positions in the business. Crossmark Global Holdings Inc. acquired a new stake in Opko Health during the 3rd quarter worth about $118,000. State of Alaska Department of Revenue acquired a new stake in Opko Health during the 4th quarter worth about $144,000. The Manufacturers Life Insurance Company grew its position in Opko Health by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 1,657 shares during the period. Psagot Investment House Ltd. grew its position in Opko Health by 20.0% during the 2nd quarter. Psagot Investment House Ltd. now owns 22,862 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 3,806 shares during the period. Finally, Prudential Financial Inc. grew its position in Opko Health by 6.1% during the 2nd quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 1,400 shares during the period. 22.94% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/08/phillip-md-et-al-frost-buys-78000-shares-of-opko-health-inc-opk-stock.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply